Oral Oncology
Volume 46, Issue 9 , Pages 630-635 , September 2010

Prognostic evaluation of oral tongue cancer: Means, markers and perspectives (I)

  • Ibrahim O. Bello

      Affiliations

    • Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, FI-90014 Oulu, Finland
    • ,
  • Ylermi Soini

      Affiliations

    • Department of Pathology and Forensic Medicine, University of Eastern Finland, Kuopio, Finland
    • ,
  • Tuula Salo

      Affiliations

    • Department of Diagnostics and Oral Medicine, Institute of Dentistry, University of Oulu, FI-90014 Oulu, Finland
    • Corresponding Author InformationCorresponding author. Tel.: +358 8 537 5592.

Received 10 May 2010 ,Revised 14 June 2010 ,Accepted 16 June 2010.

References 

  1. Rautava J, Luukkaa M, Heikinheimo K, Alin J, Grenman R, Happonen RP. Squamous cell carcinomas arising from different types of oral epithelia differ in their tumor and patient characteristics and survival. Oral Oncol. 2007;43(9):911–919
  2. Sathyan KM, Sailasree R, Jayasurya R, Lakshminarayanan K, Abraham T, Nalinakumari KR, et al. Carcinoma of tongue and the buccal mucosa represent different biological subentities of the oral carcinoma. J Cancer Res Clin Oncol. 2006;132(9):601–609
  3. Rusthoven K, Ballonoff A, Raben D, Chen C. Poor prognosis in patients with stage I and II oral tongue squamous cell carcinoma. Cancer. 2008;112(2):345–351
  4. Regezi JA, Sciubba JJ, Jordan RCK. Oral pathology: clinical, pathologic correlations. 5th ed.. St Louis (MO): Saunders Elsevier; 2008;
  5. Lim MS. RE: correlational of oral tongue cancer inversion with matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEGF) expression, by Kim S-H, Cho NH, Kim K, et al.. J Surg Oncol. 2006;93(4):253–254
  6. Sano D, Myers JN. Metastasis of squamous cell carcinoma of the oral tongue. Cancer Metastasis Rev. 2007;26(3–4):645–662
  7. Leipzig B, Cummings CW, Chung CT, Johnson JT, Sagerman RH. Carcinoma of the anterior tongue. Ann Otol Rhinol Laryngol 1982;91(1 Pt 1):94–7.
  8. Byers RM, El-Naggar AK, Lee YY, Rao B, Fornage B, Terry NHA, et al. Can we detect or predict the presence of occult nodal metastases in patients with squamous carcinoma of the oral tongue?. Head Neck. 1998;20(2):138–144
  9. Huang SF, Kang CJ, Lin CY, Fan KH, Yen TC, Wang HM, et al. Neck treatment of patients with early stage oral tongue cancer: comparison between observation, supraomohyoid dissection, and extended dissection. Cancer. 2008;112(5):1066–1075
  10. D’Cruz AK, Siddachari RC, Walvekar RR, Pantvaidya GH, Chaukar DA, Deshpande MS, et al. Elective neck dissection for the management of the N0 neck in early cancer of the oral tongue: need for a randomized controlled trial. Head Neck. 2009;31(5):618–624
  11. Haddadin KJ, Soutar DS, Oliver RJ, Webster MH, Robertson AG, MacDonald DG. Improved survival for patients with clinically T1/T2, N0 tongue tumors undergoing a prophylactic neck dissection. Head Neck. 1999;21(6):517–525
  12. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70
  13. Liu ET. Mechanism-derived gene expression signatures and predictive biomarkers in clinical oncology. Proc Natl Acad Sci USA. 2005;102(10):3531–3532
  14. Elston CW, Sloane JP, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, et al. Causes of inconsistency in diagnosing and classifying intraductal proliferations of the breast. European Commission Working Group on Breast Screening Pathology. Eur J Cancer. 2000;36(14):1769–1772
  15. Lakhani SR, Ashworth A. Microarray and histopathological analysis of tumours: the future and the past?. Nat Rev Cancer. 2001;1(2):151–157
  16. Duffy MJ, Crown J. A personalized approach to cancer treatment: how biomarkers can help. Clin Chem. 2008;54(11):1770–1779
  17. van Diest PJ, Brugal G, Baak JP. Proliferation markers in tumours: interpretation and clinical value. J Clin Pathol. 1998;51(10):716–724
  18. Alanen KA, Lintu M, Joensuu H. Image cytometry of breast carcinomas that are DNA diploid by flow cytometry: time to revise the concept of DNA diploidy?. Anal Quant Cytol Histol. 1998;20(3):178–186
  19. Balsara BR, Borges AM, Pradhan SA, Rajpal RM, Bhisey AN. Flow cytometric DNA analysis of squamous cell carcinomas of the oral cavity: correlation with clinical and histopathological features. Eur J Cancer B Oral Oncol. 1994;30B(2):98–101
  20. Hemmer J, Nagel E, Kraft K. DNA aneuploidy by flow cytometry is an independent prognostic factor in squamous cell carcinoma of the oral cavity. Anticancer Res. 1999;19(2B):1419–1422
  21. Michiels S, Koscielny S, Hill C. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005;365(9458):488–492
  22. Nimeus-Malmstrom E, Ritz C, Eden P, Johnsson A, Ohlsson M, Strand C, et al. Gene expression profilers and conventional clinical markers to predict distant recurrences for premenopausal breast cancer patients after adjuvant chemotherapy. Eur J Cancer. 2006;42(16):2729–2737
  23. Dunkler D, Michiels S, Schemper M. Gene expression profiling: does it add predictive accuracy to clinical characteristics in cancer prognosis?. Eur J Cancer. 2007;43(4):745–751
  24. Fan X, Shi L, Fang H, Cheng Y, Perkins R, Tong W. DNA microarrays are predictive of cancer prognosis: a re-evaluation. Clin Cancer Res. 2010;16(2):629–636
  25. Biganzoli E, Lama N, Ambrogi F, Antolini L, Boracchi P. Prediction of cancer outcome with microarrays. Lancet. 2005;365(9472):1683
  26. van’t Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536
  27. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van’t Veer LJ, van Dam FS, Karsenberg K, et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol. 2007;8(12):1079–1087
  28. Nyberg P, Salo T, Kalluri R. Tumor microenvironment and angiogenesis. Front Biosci. 2008;13:6537–6553
  29. Fusenig NE, Breitkreutz D, Dzarlieva RT, Boukamp P, Bohnert A, Tilgen W. Growth and differentiation characteristics of transformed keratinocytes from mouse and human skin in vitro and in vivo. J Invest Dermatol. 1983;81(1 Suppl):168s–175s
  30. Nurmenniemi S, Sinikumpu T, Alahuhta I, Salo S, Sutinen M, Santala M, et al. A novel organotypic model mimics the tumor microenvironment. Am J Pathol. 2009;175(3):1281–1291
  31. Van Dyke T, Jacks T. Cancer modeling in the modern era: progress and challenges. Cell. 2002;108(2):135–144
  32. Koivunen E, Arap W, Valtanen H, Rainisalo A, Medina OP, Heikkila P, et al. Tumor targeting with a selective gelatinase inhibitor. Nat Biotechnol. 1999;17(8):768–774
  33. Karnoub AE, Dash AB, Vo AP, Sullivan A, Brooks MW, Bell GW, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature. 2007;449(7162):557–563
  34. Heikkila P, Suojanen J, Pirila E, Vaananen A, Koivunen E, Sorsa T, et al. Human tongue carcinoma growth is inhibited by selective antigelatinolytic peptides. Int J Cancer. 2006;118(9):2202–2209
  35. McCormick DL, Mehta RG, Thompson CA, Dinger N, Caldwell JA, Moon RC. Enhanced inhibition of mammary carcinogenesis by combined treatment with N-(4-hydroxyphenyl)retinamide and ovariectomy. Cancer Res. 1982;42(2):508–512
  36. Grubbs CJ, Becci PJ, Thompson HJ, Moon RC. Carcinogenicity of N-methyl-N- nitrosourea and N-ethyl-N-nitrosourea when applied to a localized area of the hamster trachea. J Natl Cancer Inst. 1981;66(5):961–965
  37. Korpi JT, Kervinen V, Maklin H, Vaananen A, Lahtinen M, Laara E, et al. Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer. Brit J Cancer. 2008;98(4):766–775
  38. Vered M, Polak-Charcon S, Babushkin T, Dayan D. 4NQO-induced rat tongue carcinoma: an ultrastructural study. Ultrastruct Pathol. 2008;32(5):199–205
  39. Amatruda JF, Patton EE. Genetic models of cancer in zebrafish. Int Rev Cell Mol Biol. 2008;271:1–34
  40. Hu B, Zhang C, Baawo K, Qin R, Cole GJ, Lee JA, et al. Zebrafish K5 promoter driven GFP expression as a transgenic system for oral research. Oral Oncol. 2010;46(1):31–37
  41. Somasundaram K, Nijaguna MB, Kumar DM. Serum proteomics of glioma: methods and applications. Expert Rev Mol Diagn. 2009;9(7):695–707
  42. Wu JY, Yi C, Chung HR, Wang DJ, Chang WC, Lee SY, et al. Potential biomarkers in saliva for oral squamous cell carcinoma. Oral Oncol. 2010;46(4):226–231
  43. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group. J Clin Oncol 1997;15(2):594–603.
  44. Sturgeon CM, Lai LC, Duffy MJ. Serum tumour markers: how to order and interpret them. BMJ. 2009;339:b3527
  45. Yamazaki Y, Chiba I, Ishikawa M, Satoh C, Notani K, Ohiro Y, et al. Serum p53 antibodies as a prognostic indicator in oral squamous cell carcinoma. Odontology. 2008;96(1):32–37
  46. Sainger RN, Shah MH, Desai AA, Shukla SN, Shah PM, Telang SD, et al. Clinical significance of serum p53 antibodies in oral cancer. Tumori. 2006;92(2):134–139
  47. Khandavilli SD, Ceallaigh PO, Lloyd CJ, Whitaker R. Serum C-reactive protein as a prognostic indicator in patients with oral squamous cell carcinoma. Oral Oncol. 2009;45(10):912–914
  48. Ota K, Fujimori H, Ueda M, Shiniriki S, Kudo M, Jono H, et al. Midkine as a prognostic biomarker in oral squamous cell carcinoma. Brit J Cancer. 2008;99(4):655–662
  49. Krimmel M, Hoffmann J, Krimmel C, Cornelius CP, Schwenzer N. Relevance of SCC-Ag, CEA, CA 19.9 and CA 125 for diagnosis and follow-up in oral cancer. J Craniomaxillofac Surg. 1998;26(4):243–248
  50. Tamaki S, Sanefuzi N, Kawakami M, Aoki K, Imai Y, Yamanaka Y, et al. Association between soluble MICA levels and disease stage IV oral squamous cell carcinoma in Japanese patients. Human Immunol. 2008;69(2):88–93
  51. Shang ZJ, Li JR, Li ZB. Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma. J Oral Maxillofac Surg. 2007;65(1):17–21
  52. Zhong LP, Zhu HG, Zhang CP, Chen WT, Zhang ZY. Detection of serum Cyfra 21-1 in patients with primary oral squamous cell carcinoma. Int J Oral Maxillofac Surg. 2007;36(3):230–234
  53. Nagler RM, Barak M, Peled M, Ben-Aryeh H, Filatov M, Laufer D. Early diagnosis and treatment monitoring roles of tumor markers Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer. 1999;85(5):1018–1025
  54. Hamana K, Uzawa K, Ogawara K, Shiiba M, Bukawa H, Yokoe H, et al. Monitoring of circulating tumour-associated DNA as a prognostic tool for oral squamous cell carcinoma. Brit J Cancer. 2005;92(12):2181–2184
  55. Raval GN, Patel DD, Parekh LJ, Patel JB, Shah MH, Patel PS. Evaluation of serum sialic acid, sialyltransferase and sialoproteins in oral cavity cancer. Oral Dis. 2003;9(3):119–128
  56. Hedstrom J, Grenman R, Ramsay H, Finne P, Lundin J, Haglund C, et al. Concentration of free hCGbeta subunit in serum as a prognostic marker for squamous-cell carcinoma of the oral cavity and oropharynx. Int J Cancer. 1999;84(5):525–528
  57. Duffy SA, Taylor JM, Terrell JE, Islam M, Li Y, Fowler KE, et al. Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer. 2008;113(4):750–757
  58. Pradhan-Palikhe P, Vesterinen T, Tarkkanen J, Leivo I, Sorsa T, Salo T, et al. Plasma level of tissue inhibitor of matrix metalloproteinase-1 but not that of matrix metalloproteinase-8 predicts survival in head and neck squamous cell cancer. Oral Oncol. 2010;46(7):514–518
  59. Nagler RM. Saliva as a tool for oral cancer diagnosis and prognosis. Oral Oncol. 2009;45(12):1006–1010
  60. Matharoo-Ball B, Miles AK, Creaser CS, Ball G, Rees R. Serum biomarker profiling in cancer studies: a question of standardisation?. Vet Comp Oncol. 2008;6(4):224–247
  61. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park NH, et al. Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. Gastroenterology 2010;138(3):949–57, e1–7.
  62. Woolgar JA. Histopathological prognosticators in oral and oropharyngeal squamous cell carcinoma. Oral Oncol. 2006;42(3):229–239
  63. Garavello W, Spreafico R, Gaini RM. Oral tongue cancer in young patients: a matched analysis. Oral Oncol. 2007;43(9):894–897
  64. Liao CT, Wang HM, Hsieh LL, Chang JT, Ng SH, Hsueh C, et al. Higher distant failure in young age tongue cancer patients. Oral Oncol. 2006;42(7):718–725
  65. Hyam DM, Conway RC, Sathiyaseelan Y, Gebski V, Morgan GJ, Walker DM, et al. Tongue cancer: do patients younger than 40 do worse?. Aust Dent J. 2003;48(1):50–54
  66. Atula S, Grenman R, Laippala P, Syrjanen S. Cancer of the tongue in patients younger than 40 years. A distinct entity? Arch Otolaryngol Head Neck Surg 1996;122(12):1313–9.
  67. Annertz K, Anderson H, Biorklund A, Moller T, Kantola S, Mork J, et al. Incidence and survival of squamous cell carcinoma of the tongue in Scandinavia, with special reference to young adults. Int J Cancer. 2002;101(1):95–99
  68. Davidson BJ, Root WA, Trock BJ. Age and survival from squamous cell carcinoma of the oral tongue. Head Neck. 2001;23(4):273–279
  69. Kantola S, Parikka M, Jokinen K, Hyrynkangs K, Soini Y, Alho OP, et al. Prognostic factors in tongue cancer – relative importance of demographic, clinical and histopathological factors. Brit J Cancer. 2000;83(5):614–619
  70. Veness MJ, Morgan GJ, Sathiyaseelan Y, Gebski V. Anterior tongue cancer: age is not a predictor of outcome and should not alter treatment. Anz J Surg. 2003;73(11):899–904
  71. Siegelmann-Danieli N, Hanlon A, Ridge JA, Padmore R, Fein DA, Langer CJ. Oral tongue cancer in patients less than 45 years old: institutional experience and comparison with older patients. J Clin Oncol. 1998;16(2):745–753
  72. Pitman KT, Johnson JT, Wagner RL, Myers EN. Cancer of the tongue in patients less than forty. Head Neck. 2000;22(3):297–302
  73. Friedlander PL, Schantz SP, Shaha AR, Yu G, Shah JP. Squamous cell carcinoma of the tongue in young patients: a matched-pair analysis. Head Neck. 1998;20(5):363–368
  74. Popovtzer A, Shpitzer T, Bahar G, Marshak G, Ulanovski D, Feinmesser R. Squamous cell carcinoma of the oral tongue in young patients. Laryngoscope. 2004;114(5):915–917
  75. Berrino F, Gatta G. Variation in survival of patients with head and neck cancer in Europe by the site of origin of the tumours. EUROCARE Working Group. Eur J Cancer 1998;34(14 Spec No):2154–61.
  76. Dickman PW, Hakulinen T, Luostarinen T, Pukkala E, Sankila R, Soderman B, et al. Survival of cancer patients in Finland 1955–1994. Acta Oncol. 1999;38(Suppl 12):1–103
  77. Zheng Y, Kirita T, Kurumatani N, Sugimura M, Yonemasu K. Trends in oral cancer mortality in Japan: 1950–1993. Oral Dis. 1999;5(1):3–9
  78. Mathew Iype E, Pandey M, Mathew A, Thomas G, Sebastian P, Krishnan Nair M. Squamous cell carcinoma of the tongue among young Indian adults. Neoplasia. 2001;3(4):273–277
  79. Shiboski CH, Schmidt BL, Jordan RC. Racial disparity in stage at diagnosis and survival among adults with oral cancer in the US. Community Dent Oral Epidemiol. 2007;35(3):233–240
  80. Macfarlane GJ, Sharp L, Porter S, Franceschi S. Trends in survival from cancers of the oral cavity and pharynx in Scotland: a clue as to why the disease is becoming more common?. Brit J Cancer. 1996;73(6):805–808
  81. Lo WL, Kao SY, Chi LY, Wong YK, Chang RC. Outcomes of oral squamous cell carcinoma in Taiwan after surgical therapy: factors affecting survival. J Oral Maxillofac Surg. 2003;61(7):751–758
  82. El-Husseiny G, Kandil A, Jamshed A, Khafaga Y, Saleem M, Allam A, et al. Squamous cell carcinoma of the oral tongue: an analysis of prognostic factors. Brit J Oral Maxillofac Surg. 2000;38(3):193–199
  83. Yoshida K, Kashima K, Suenaga S, Nomi N, Shuto J, Suzuki M. Immunohistochemical detection of cervical lymph node micrometastases from T2N0 tongue cancer. Acta Otolaryngol. 2005;125(6):654–658
  84. Kaya S, Yilmaz T, Gursel B, Sarac S, Sennaroglu L. The value of elective neck dissection in treatment of cancer of the tongue. Am J Otolaryngol. 2001;22(1):59–64
  85. Sparano A, Weinstein G, Chalian A, Yodul M, Weber R. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg. 2004;131(4):472–476
  86. van den Brekel MWM, Castelijns JA, Snow GB. Diagnostic evaluation of the neck. Otolaryngol Clin North Am. 1998;31(4):601–620
  87. Keski-Santti H, Kontio R, Leivo I, Tornwall J, Matzke S, Makitie AA, et al. Sentinel lymph node biopsy as an alternative to wait and see policy in patients with small T1 oral cavity squamous cell carcinoma. Acta Otolaryngol. 2008;128(1):98–102
  88. O’Donnell RK, Kupferman M, Wei SJ, Singhal S, Weber R, O’Malley B, et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene. 2005;24(7):1244–1251
  89. Roepman P, Wessels LF, Kettelarij N, Kemmeren P, Miles AJ, Lijnzaad P, et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet. 2005;37(2):182–186
  90. Nguyen ST, Hasegawa S, Tsuda H, Tomioka H, Ushijima M, Noda M, et al. Identification of a predictive gene expression signature of cervical lymph node metastasis in oral squamous cell carcinoma. Cancer Sci. 2007;98(5):740–746
  91. Colella S, Richards KL, Bachinski LL, Baggerly KA, Tsavachidis S, Lang JC, et al. Molecular signatures of metastasis in head and neck cancer. Head Neck. 2008;30(10):1273–1283

PII: S1368-8375(10)00189-2

doi: 10.1016/j.oraloncology.2010.06.006

Oral Oncology
Volume 46, Issue 9 , Pages 630-635 , September 2010

Article Tools

* Image Usage & Resolution